At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 67 enrolled
Drug / intervention
MK-8777 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Double Blind, Placebo Controlled, Randomized, Two Period 4-Arm Trial to Investigate the Dose-Related Efficacy and Safety of Org 26576 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
In Brief
A Phase 2 clinical trial evaluating MK-8777 and Placebo for Attention Deficit Hyperactivity Disorder. Completed, enrolled 67 participants.
Detailed Summary
This is a Phase 2 multicenter, randomized, double-blind trial of MK-8777 (Org 26576, SCH 900777) in adult subjects with Attention-Deficit/Hyperactivity Disorder (ADHD). MK-8777 or placebo will be administered in a crossover fashion for two 3-week treatment periods. The two 3-week treatment periods will be separated by a 2-week placebo washout period. The primary objective is to compare the efficacy of various doses of MK-8777 to that of placebo in the treatment of ADHD symptoms in adults.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAttention Deficit Hyperactivity Disorder
Countries--
Collaborators--
Timeline
Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedFeb 2008
Enrollment StartApr 2008
Primary CompletionMar 2009
Study CompletionMar 2009
TodayJul 2026
First PostedFeb 8, 2008
Enrollment StartApr 1, 2008
Primary CompletionMar 2, 2009
Study CompletionMar 9, 2009
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 18.4 years ago
Interventions
MK-8777drug
Placebodrug